The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
To expand access to breast cancer screening for patients across Virginia, UVA Health is rolling out a new mobile mammography coach.
